药物涂层支架与金属裸支架治疗ST段抬高型心肌梗死的临床价值比较

目的:评价药物涂层支架(DES)与金属裸支架(BMS)在急性心肌梗死患者中应用的安全性和有效性。方法:选择2003年1月-2010年12月,在我院确诊的急性ST段抬高型心肌梗死(STEMI)167例患者,其中使用BMS 65例,DES 102例。对比分析两组患者住院期间和出院后1年内的主要心血管或脑血管事件(MAACE)的发生情况及支架内血栓形成的发生率。结果:至随访结束,BMS组有1例患者猝死,5例出现复发心绞痛。DES组有1例突发急性左心衰后死亡,1例复发心绞痛和1例发生亚急性支架内血栓。结论:DES应用于STEMI具有较好的安全性,其术后MAACE发生率较BMS低。     

中性粒细胞／淋巴细胞比值与药物支架内再狭窄关系

目的：探讨经皮冠状动脉支架植入术前中性粒细胞／淋巴细胞比值（Neutrophil-to-LymphocyteRatio,NLR）与患者药物支架（DrugElutingStent,DES）植入后发生支架内再狭窄（In—StentRestenosis,ISR）的关系。方法：回顾性分析2012年01月至2012年10月间有DES植入史并再次入院接受冠脉造影的92例患者（平均年龄65．22±9．73岁）的血液学检查、既往冠脉造影结果及再次冠脉造影结果。根据DES植入前的NLR的四分位点将所有入选患者分为3组：最低三分位组（n=31,0．91-1．83）,中间三分位（n=30,1．87—2．63）,最高三分位（n=31,2．66—4．67）,比较3组间ISR发生率有无差异。结果：再狭窄发生在最低NLR三分位的有3例（9．68％）,发生在中间NLR三分位组的有2例（6．67％）,而有4例（12．90％）发生在NLR最高三分位组（P=0．714）,3组之间的差异无统计学意义。结论：因稳定或不稳定型心绞痛而植入药物支架的患者,其术前NLR同支架术后ISR的发生无明显相关性。NLR不能作为DES植入后发生再狭窄的预测指标。     

药物洗脱支架治疗急性心肌梗死患者临床随访观察

目的:探讨药物洗脱支架在急性心肌梗死(AMI)入住我院CCU后行急诊经皮冠状动脉介入治疗(PCI)的安全性和有效性.方法:选择2007年1月至2007年12月因急性心肌梗死入住我院CCU的220例急性心肌梗死患者,其中于发病12小时内行急诊手术治疗的患者200例,急诊手术仅处理梗死相关血管的靶病变,均植入药物洗脱支架,评价手术成功率、并发症、随访期间心脏不良事件发生率、再狭窄率等.结果:200例患者急诊手术治疗均获得成功,植入支架数量为1.41±0.711枚,未发生与介入治疗有关的严重并发症,住院期间发生心源性死亡2例,非心源性死亡1例,无院内支架内血栓形成、再次心梗,临床随防7.3±1.9(5-15)个月,136例患者复查了冠状动脉造影,造影随访率72.3%,随访终点内死亡5例(死亡率2.66%),含心源性死亡3例,非心源性死亡2例,其中再发心肌梗死1例,6例患者进行了再次靶血管血运重建(3.19%).结论:药物洗脱支架在急性心肌梗死患者行急诊PCI治疗中安全可行,且院内、术后7个月随访观察显示疗效显著,并明显降低靶血管再狭窄率.     

MHR、血清ESM-1、sST2与急性ST段抬高型心肌梗死患者直接PCI术中慢血流/无复流的关系及对近期预后的预测价值

摘要 目的：探讨单核细胞与高密度脂蛋白胆固醇比值（MHR）、血清内皮细胞特异性分子-1（ESM-1）、可溶性致癌抑制因子2（sST2）与急性ST段抬高型心肌梗死（STEMI）患者直接经皮冠状动脉介入治疗（PPCI）术中慢血流/无复流（SRF/NRF）的关系及对其近期预后的预测价值。方法：选取2019年1月～2022年4月首都医科大学附属北京朝阳医院心内科收治的187例接受PPCI术的急性STEMI患者为急性STEMI组,根据PPCI术中心肌梗死溶栓治疗（TIMI）血流分级分为SRF/NRF组47例和无SRF/NRF组140例,随访6个月,根据是否发生主要不良心血管事件分为预后不良组和预后良好组,另选取同期56名体检健康志愿者为对照组。收集急性STEMI患者临床资料,计算MHR并检测血清ESM-1、sST2水平。采用Spearman相关性分析SRF/NRF患者MHR和血清ESM-1、sST2水平与TIMI血流分级的相关性,多因素Logistic回归分析急性STEMI患者PPCI后近期预后不良的影响因素,受试者工作特征（ROC）曲线分析MHR和血清ESM-1、sST2水平对急性STEMI患者PPCI后近期预后不良的预测价值。结果：急性STEMI组MHR和血清ESM-1、sST2水平高于对照组（P＜0.05）。SRF/NRF组MHR和血清ESM-1、sST2水平高于无SRF/NRF组（P＜0.05）。SRF/NRF患者MHR和血清ESM-1、sST2水平与TIMI血流分级呈负相关（P＜0.05）。左心室射血分数升高为急性STEMI患者PPCI后近期预后不良的独立保护因素,年龄增加、SRF/NRF和MHR、ESM-1、sST2升高则为独立危险因素（P＜0.05）。ROC曲线分析显示,MHR和血清ESM-1、sST2水平联合预测急性STEMI患者PPCI后近期预后不良的曲线下面积（AUC）大于MHR、ESM-1、sST2单独预测。结论：急性STEMI患者MHR和血清ESM-1、sST2水平升高与PPCI术中SRF/NRF和近期预后不良密切相关,三者联合预测急性STEMI患者近期预后不良的价值较高。     

自膨式支架辅助弹簧圈栓塞治疗颅内动脉瘤的疗效及安全性分析

摘要 目的：探讨自膨式支架辅助弹簧圈栓塞治疗颅内动脉瘤的疗效及安全性。方法：回顾性分析2014年1月-2019年1月我院采取自膨式支架辅助弹簧圈栓塞治疗颅内动脉瘤患者159例（A组）及采取单纯弹簧圈栓塞治疗颅内动脉瘤患者178例（B组）,比较两种手术方法治疗颅内动脉瘤的手术时间、术后住院时间、随访时间、手术相关并发症发生率并通过格拉斯哥（GOS）预后评分、Raymond分级比较2种治疗方法的安全性及有效性。结果：两组手术时间、术后住院时间、随访时间比较差异无统计学意义（P＞0.05）。两组术后出血及缺血事件发生率差异有统计学意义（P＜0.05）,脑积水、肺炎发生率、致死率及致残率差异无统计学意义（连续校正后P=1）。术后1月内及术后12个月随访GOS评分,A组评分高于B组,差异具有统计学意义（P＜0.05）;术后1月内及术后12个月随访Raymond分级,A组优于B组,差异具有统计学意义（P＜0.05）。结论：自膨式支架辅助弹簧圈栓塞治疗颅内动脉瘤栓塞效果明显且术后并发症少,对于颅内动脉瘤患者在弹簧圈栓塞基础上应用自膨式支架辅助可提高手术安全性及栓塞的疗效。     

急性ST段抬高型心肌梗死患者血清Lp(a)、UA、GGT与冠状动脉病变和PCI术后主要心血管不良事件的关系研究

摘要 目的：探讨急性ST段抬高型心肌梗死（STEMI）患者血清脂蛋白(a)[Lp(a)]、尿酸（UA）、γ-谷氨酰转移酶（GGT）与冠状动脉病变和经皮冠状动脉介入治疗（PCI）术后主要心血管不良事件（MACE）的关系。方法：选取2019年1月～2022年7月安徽医科大学第二附属医院心血管内科收治的100例接受PCI术治疗的急性STEMI患者为STEMI组,根据Gensini积分将其分为非重度病变组56例和重度病变组44例,PCI术后随访3个月,根据是否发生MACE分为MACE亚组和非MACE亚组,另选取同期50名冠脉造影检查排除冠心病者为对照组。收集急性STEMI患者的临床资料,并检测血清Lp(a)、UA、GGT水平。分析急性STEMI患者血清Lp(a)、UA、GGT水平与Gensini评分的相关性及PCI术后MACE的影响因素。结果：与对照组比较,STEMI组血清Lp(a)、UA、GGT水平升高（P＜0.05）。重度病变组血清Lp(a)、UA、GGT水平高于非重度病变组（P＜0.05）。Spearman相关系数分析显示,急性STEMI患者血清Lp(a)、UA、GGT水平与Gensini评分呈正相关（P＜0.05）。随访3个月,100例急性STEMI患者PCI术后MACE发生率为21.00％（21/100）。多因素Logistic回归分析显示,年龄增加、KILLIP心功能分级≥Ⅲ级和Lp(a)、UA、GGT升高为PCI术后MACE的独立危险因素,左心室射血分数（LVEF）升高为独立保护因素（P＜0.05）。结论：急性STEMI患者血清Lp(a)、UA、GGT水平升高,与冠状动脉病变严重程度和PCI术后MACE密切相关,可能成为急性STEMI患者PCI术后MACE的辅助预测指标。     

支架置入术治疗椎动脉起始段狭窄的临床疗效及术后支架内再狭窄的影响因素分析

摘要 目的：研究支架置入术（SI）治疗椎动脉起始段狭窄（VAOS）的临床疗效及术后支架内再狭窄（ISR）的影响因素。方法：选择从2018年1月到2020年2月在我院接受SI治疗的VAOS患者83例纳入本次研究。剔除1例手术失败及1例死亡患者的病例后,对剩余81例患者根据患者是否发生ISR,将其分成ISR组28例和无ISR组53例。随访分析患者的临床疗效,对患者发生ISR进行单因素及多因素Logistic回归分析,同时分析患者美国国立卫生院卒中量表（NIHSS）评分与血管狭窄情况及血流动力学指标的相关性。结果：83例VAOS患者接受SI术式治疗后,手术成功率为98.80%（82/83）。术后有3例患者发生动脉痉挛,另有1例患者在术后7 d由于继发脑出血而死亡,并发症的总发生率为4.82%（4/83）。ISR组的高脂血症、合并颈内动脉的狭窄、椎动脉的狭窄部位为双侧、支架类型为裸支架的比例分别高于无ISR组（均P＜0.05）。根据Pearson法分析相关性显示,患者NIHSS评分与血管狭窄率、狭窄血管长度、收缩期峰值流速（PSV）和舒张期末流速（EDV）均呈正相关（P＜0.05）。根据Logistic回归分析显示,患者发生ISR影响因素包含高脂血症和支架类型为裸支架,以及合并颈内动脉的狭窄和并发双侧椎动脉的狭窄（P＜0.05）。结论：SI术式治疗的VAOS患者的临床疗效较好,且术后ISR的影响因素主要包含高脂血症和支架类型为裸支架,以及合并颈内动脉的狭窄和并发双侧椎动脉的狭窄,临床上应引起相应的重视。     

急性下壁心肌梗死急诊PCI术中应用临时起搏器与阿托品的对比研究

目的：探讨临时起搏器与阿托品在急性下壁心肌梗死急诊经皮冠状动脉介入治疗（PCI）中应用的疗效。方法：入选2012 年2 月至2013 年8 月我院收治的发病12 小时内,诊断为急性下壁心肌梗死并接受急诊PCI治疗的患者92 例,依据治疗方法的不同 将病例分为临时起搏组和阿托品组,并对病例进行为期一年的追踪随访,收集患者平均住院天数、平均住院费用、再灌注心律失 常、心肌梗死后心绞痛、心肌梗死后心衰发生率资料。结果：临时起搏组的平均住院天数、平均住院费用、心肌梗死后心绞痛、心肌 梗死后心衰发生率均显著低于阿托品治疗组（P 均<0.05）,阿托品治疗组的再灌注心律失常发生率则明显低于临时起搏组（P<0. 05）。结论：急性下壁心肌梗死急诊PCI中应用临时起搏器,具有治疗成本低,降低心血管事件发生率的优点,而阿托品治疗在改 善再灌注心律失常的疗效上则显著优于临时起搏治疗。     

药物洗脱支架植入术与冠状动脉旁路移植术治疗冠心病多支病变伴糖尿病患者的临床效果分析

目的:比较药物洗脱支架(DES)植入术及冠状动脉旁路移植术(CABG)治疗冠心病多支病变伴糖尿病患者的近期及远期临床疗效。方法:回顾性分析2014年1月~2016年10月在哈尔滨医科大学附属第一医院经冠状动脉造影证实为多支血管病变并伴有糖尿病的患者186例,根据血运重建方式的不同分为DES组及CABG组,随访50.5±14.3个月,观察两组患者住院期间及随访期主要不良心脑血管事件(包括非致死心肌梗死、脑卒中、再次血运重建、全因死亡)的发生情况。结果:在所有入选患者中,DES组有更多双支病变(P0.05),CABG组三支病变较多(P0.05),两组在完全血运重建方面无显著性差异(P0.05)。住院期间,CABG组死亡2例(2.3%),DES组死亡1例(1.0%),死亡率比较无统计学意义(P0.05)。两组均未出现非致死性心肌梗死、脑卒中、再次血运重建。出院后对186例入选患者随访,其中失访11例(DES组5例,CABG组6例)。随访期间CABG组发生非致死性心肌梗死1例(1.3%)、脑卒中6例(7.5%)、全因死亡10例(12.5%),DES组发生非致死性心肌梗死5例(5.3%)、脑卒中3例(3.2%)、全因死亡9例(9.5%),两组间比较差异无统计学意义(P0.05);而CABG组再次血运重建2例(2.5%),DES组15例(15.8%),两组比较差异具有统计学意义(P0.01)。结论:行DES置入术或CABG术治疗冠心病多支病变伴糖尿病患者,住院期间主要心脑血管不良事件发生率、远期非致死性心肌梗死、脑卒中、全因死亡发生情况均无显著性差异,但DES组再次血运重建率明显升高,可能与糖尿病患者较高的再狭窄率有关。     

比伐卢定联合替罗非班在高血栓负荷拟行PPCI治疗的急性ST段抬高型心肌梗死患者中的应用价值

目的:探讨替罗非班与比伐卢定联合治疗在高血栓负荷拟行直接经皮冠状动脉介入(PPCI)的急性ST段抬高型心肌梗死(STEMI)患者中的应用价值。方法:选取我院于2018年3月~2020年3月期间收治的127例高血栓负荷拟行PPCI治疗的STEMI患者。将所有患者按照入院顺序,单号分为对照组(替罗非班治疗),双号分为观察组(比伐卢定联合替罗非班治疗),分别为63例和64例。对比两组术后24 h、术后30 d支架内血栓事件、30 d内的出血事件发生率,对比两组心肌梗死溶栓试验(TIMI)血流分级变化、心功能及肌酸激酶同工酶(CKMB)峰值时间及CKMB峰值,记录两组术后不良心血管事件发生率及住院时间。结果:两组术后24 h、术后30 d均未发生支架内血栓事件,观察组30 d内的出血事件发生率较对照组低(P<0.05)。两组住院时间组间对比无明显差异(P>0.05)。两组术后1个月TIMI血流分级为Ⅲ级的占比高于术前同一分级,TIMI血流分级为0~Ⅰ级、Ⅱ级的占比低于术前同一分级(P<0.05)。观察组术后7 d左心室收缩末期内径(LVESD)、CKMB峰值小于对照组,左心室射血分数(LVEF)高于对照组,CKMB峰值时间短于对照组(P<0.05)。两组心血管不良事件总发生率对比无差异(P>0.05)。结论:比伐卢定联合替罗非班治疗高血栓负荷拟行PPCI的STEMI患者,可改善患者心功能,减少心肌损伤,改善TIMI血流分级,同时还可减少30 d内的出血事件发生率。     

Drug-Eluting versus Bare-Metal Stent for Treatment of Saphenous Vein Grafts: A Meta-Analysis

Background

Saphenous vein grafts develop an aggressive atherosclerotic process and the efficacy of drug eluting stents (DES) in treating saphenous vein graft (SVG) lesions has not been convincingly demonstrated. The aim of this study was to review and analyze the current literature for controlled studies comparing DES versus bare metal stents (BMS) for treatment of SVG stenoses.

Methodology/Principal Findings

We searched several scientific databases and conference proceedings up to March 15, 2010 for controlled studies comparing target vessel revascularization (TVR) between DES and BMS. Summary odds ratios (OR) for the primary endpoint TVR and secondary endpoints infarction, stent thrombosis and death were calculated using random-effect models. A total of 29 studies (3 randomized controlled trials RCT) involving 7549 (202 in RCT) patients were included. The need for target vessel revascularization in the DES group tended to be lower compared to BMS for the 3 RCT (OR 0.50 [0.24–1.00]; p = 0.051) and for observational studies (0.62 [0.49–0.79]; p<0.001). There was no significant difference in the risk for myocardial infarction in the RCT (OR 1.25 [0.22–6.99]; p = 0.250) but a lower risk for DES based on the observational studies 0.68 [0.49–0.95]; p = 0.023. The risk for stent thrombosis was found to be non-different in the RCT (OR 0.78 [0.03–21.73], p = 0.885) while it was in favor of DES in the observational studies (0.58 [0.38 – 0.84]; p<0.001). The mortality was not significantly different between DES and BMS in the RCT''s (OR 2.22 [0.17 – 29.50]; p = 0.546) while the observation studies showed a decreased mortality in the DES group (0.69 [0.55–0.85]; p<0.001).

Conclusion

DES may decrease TVR rate in treatment of SVG stenoses. No differences in reinfarction rate, stent thrombosis or mortality was found between the DES and BMS groups in the RCT''s while the observational data showed lower risk for myocardial infarction, stent thrombosis and death in the DES group. This may be a result of patient selection bias in the observational studies or represent a true finding that was not the detected in the RCT analysis due to limited statistical power.     

Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents

BackgroundAlthough the introduction of drugeluting stents (DES) has been associated with an impressive reduction in target vessel revascularisation, there has been concern about the safety profile. The aim of this study was to determine the incidence of stent thrombosis in real-world patients and evaluate the contribution of drug-eluting stents. Methods A prospective observational cohort study was conducted at a high-volume centre in Utrecht, the Netherlands. All patients who underwent a percutaneous coronary intervention (PCI) between 1 January and 31 December 2005 were evaluated. The patients were pretreated with aspirin and clopidogrel, which was continued for six months in bare metal stents (BMS) and 12 months in DES. ResultsIn 2005, 1309 patients underwent a percutaneous coronary intervention procedure with stent implantation. After a median follow-up of nine months, 1.8% (n=23) of the patients had suffered from stent thrombosis. Two cases could be attributed to incorrect use of antiplatelet agents. In 8/23 cases, a technical reason was found such as an unrecognised dissection or stent underexpansion. The timing of stent thrombosis was acute in 1/23 patients, subacute in 20/23 patients and late in 2/23 patients. In both cases of late stent thrombosis, a BMS had been used. There were no differences in stent thrombosis rates between DES and BMS (1.4 vs. 1.9%, ns.). This is remarkable since DES were used in more complex and longer lesions. ConclusionThe use of DES in routine daily practice does not appear to be associated with a higher rate of stent thrombosis than BMS. (Neth Heart J 2007;15:382-6).     

不同类型的急性冠脉综合征患者血清热休克蛋白60浓度比较研究

目的：了解急性冠脉综合征（ACS）发作时热休克蛋白60（HSP60）及其抗体的血清浓度变化情况。方法：测定各类不稳定性心绞痛（UA,n=32）、S-T段抬高性心肌梗死（STEMI,n=16）和非ST段抬高性心肌梗死（NSTEMI,n=8）和健康对照（n=38）血清HSP60及其抗体的浓度并作统计学比较。结果：各型ACS患者血清HSP60和抗体水平均显著高于对照组（P〈0.05）,且STEMI患者血清HSP和抗体水平显著高于UA和NSTEMI患者（P〈0.05）。结论：测定患者血清HSP60水平可以用于协助ACS诊断和疾病进程监测。     

Does glycoprotein IIB/IIIA resistance exist?

Platelet function testing is not embedded into routine clinical practice, because no optimal, easy, reproducible and multipathway platelet aggregation test can be accomplished in vitro. Only recently, the relationship between the level of platelet aggregation inhibition by platelet inhibitors and clinical outcome in acute myocardial infarction became more clear.1-5 High platelet reactivity was found in patients who experienced stent thrombosis, and patients with clopidogrel resistance were at increased risk of recurrent atherothrombotic events.1,2 Furthermore, in ST-elevation myocardial infarction (STEMI) increased levels of platelet aggregation were found compared with unstable angina or control patients.4 In a thrombolysis study, higher platelet receptor occupancy was coupled with better angiographic and electrocardiographic outcome.     

Stent Thrombosis is the Primary Cause of ST-Segment Elevation Myocardial Infarction following Coronary Stent Implantation: A Five Year Follow-Up of the SORT OUT II Study

Background

The widespread use of coronary stents has exposed a growing population to the risk of stent thrombosis, but the importance in terms of risk of ST-segment elevation myocardial infarctions (STEMIs) remains unclear.

Methods

We studied five years follow-up data for 2,098 all-comer patients treated with coronary stents in the randomized SORT OUT II trial (mean age 63.6 yrs. 74.8% men). Patients who following stent implantation were readmitted with STEMI were included and each patient was categorized ranging from definite- to ruled-out stent thrombosis according to the Academic Research Consortium definitions. Multivariate logistic regression was performed on selected covariates to assess odds ratios (ORs) for definite stent thrombosis.

Results

85 patients (4.1%), mean age 62.7 years, 77.1% men, were admitted with a total of 96 STEMIs, of whom 60 (62.5%) had definite stent thrombosis. Notably, definite stent thrombosis was more frequent in female than male STEMI patients (81.8% vs. 56.8%, p = 0.09), and in very late STEMIs (p = 0.06). Female sex (OR 3.53 [1.01–12.59]) and clopidogrel (OR 4.43 [1.03–19.01]) was associated with increased for definite stent thrombosis, whereas age, time since stent implantation, use of statins, initial PCI urgency (STEMI [primary PCI], NSTEMI/unstable angina [subacute PCI] or stable angina [elective PCI]), and glucose-lowering agents did not seem to influence risk of stent thrombosis.

Conclusion

In a contemporary cohort of coronary stented patients, stent thrombosis was evident in more than 60% of subsequent STEMIs.     

Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases

Subacute stent thrombosis (SAST) is a major thrombotic complication of coronary stenting. Its occurrence has been substantially reduced by thienopyridine treatment. However, information on clinical profile of patients with SAST in clopidogrel era is limited. In order to define the incidence and factors predisposing to stent thrombosis, we analyzed the computerized angiographic database of three interventional cardiology centers. Out of a total number of 5903 percutaneous coronary interventions (PCIs) with stent implantation, we found 10 patients with SAST (0.17%). The indication for PCI was usually an early invasive approach (90%) during an acute coronary syndrome. All patients were treated with an apparently optimal antithrombotic regimen (90% received heparin or LMWH and 70% received IIb/IIIa receptor inhibitors and all given aspirin). In each of the patients, we could identify high-risk angiographic findings. SAST presentation was always clinically significant with definite myocardial infarction in 100% of cases. 80% of cases occurred during the first six days post PCI. Two patients had a recurrent event. Finally, despite earlier reports of atorvastatin-mediated inhibition of clopidogrel activation we did not find any patient with SAST taking both drugs. Thus, patients with stent thrombosis during thienopyridine treatment usually exhibit high-risk angiographic features. Prospective studies should be performed to elucidate drug interactions that may reduce clopidogrel efficacy and contribute to stent thrombosis.     

覆膜支架封堵治疗食管胃吻合口-胸腔瘘的临床疗效

目的：探讨采用自膨式覆膜支架封堵治疗食管胃吻合口-胸腔瘘的,临床价值及其安全性。方法：6例经碘水造影检查证实的食管胃吻合口-胸腔瘘患者,植入覆膜支架后,持续性胸腔引流,抗感染治疗。结果：6例患者共植入7枚支架,支架展开良好,1枚移位。有效率6／7（86％）。置入覆膜支架后,既封堵了瘘口又解决了进食问题,控制了感染。结论：采用自膨式覆膜支架封堵治疗食管胃吻合口-胸腔瘘具有较高的临床价值及安全性。     

Stent implantation at the site of the myocardial bridge after myocardial infarction. Long-term results

Although myocardial bridge is asymptomatic in most patients, it can lead to myocardial ischemia, myocardial infarction, cardiac arrhythmias, and sudden death. The authors report the case of a symptomatic myocardial bridge treated by classical stenting of the mid left anterior descending artery. The outcome was good. A control coronary angiography performed 36 months later showed no significant restenosis. No recurrence of angina during five years follow-up was observed.     

协同护理干预对心肌梗死患者康复及照顾者的生活质量和照顾能力的影响

目的：探讨协同护理对心肌梗死患者康复及照顾着生活质量的护理效果。方法：选取60例心肌梗死患者,随机分为对照组和试验组,各30例。对照组采用常规护理,试验组在对照组的基础上采用协同护理进行干预,观察两组患者在死亡、再梗死、梗死后心绞痛、严重心律失常、心力衰竭等临床并症状及生活自理能力方面的差异,采用总体健康状况量表及照顾能力测量表评价干预前后照顾者生活质量与照顾能力。结果：两组患者生活自理能力无差异（P〉0．05）,试验组梗死后心绞痛的发生率低于对照组（P〈0．05）;试验组照顾者的照顾能力及生活质量显著优于对照组,差异有统计学意义（P〈0．01）。结论：协同护理能明显提高心肌梗死患者照顾者的照顾能力及生活质量,利于患者康复。